Jo Masayasu, Yasui Kohichiroh, Kirishima Toshihiko, Shima Toshihide, Niimi Toshihisa, Katayama Takayuki, Mori Takahiro, Funaki Jun, Sumida Yoshio, Fujii Hideki, Takami Shiro, Kimura Hiroyuki, Mitsumoto Yasuhide, Minami Masahito, Yamaguchi Kanji, Yoshinami Naomi, Mizuno Masayuki, Sendo Rei, Tanaka Saiyu, Shintani Hiroyuki, Kagawa Keizo, Okanoue Takeshi, Itoh Yoshito
Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Molecular Gastroenterology and Hepatology, North Medical Center Kyoto Prefectural University of Medicine, Yosano, Japan.
Hepatol Res. 2014 Dec;44(13):1329-38. doi: 10.1111/hepr.12308. Epub 2014 Apr 2.
Sorafenib is the standard systemic therapy for patients with advanced hepatocellular carcinoma (HCC). We aimed to assess the efficacy and safety of sorafenib therapy in very elderly patients aged 80 years and older with advanced HCC.
In a retrospective multicenter study in Japan, we reviewed 185 patients (median age, 71 years; 82% male; 95% Child-Pugh class A) with advanced HCC who received sorafenib therapy. Data were compared between 24 (13%) patients aged 80 years and older and 161 (87%) patients aged less than 80 years. We used propensity score matching to adjust for differences between the two groups.
Median overall survival was 10.6 months in all patients: 11.7 months in patients aged 80 years and older and 10.5 months in those aged less than 80 years. There were no significant differences in overall survival, tumor response, and frequency and severity of drug-related adverse events between patients aged 80 years and older and those aged less than 80 years in both the entire study cohort and the propensity-matched cohort.
Sorafenib may be effective and well tolerated, even in patients with advanced HCC who are aged 80 years and older, as well as those aged less than 80 years.
索拉非尼是晚期肝细胞癌（HCC）患者的标准全身治疗药物。我们旨在评估索拉非尼治疗80岁及以上老年晚期HCC患者的疗效和安全性。
在日本进行的一项回顾性多中心研究中，我们回顾了185例接受索拉非尼治疗的晚期HCC患者（中位年龄71岁；82%为男性；95%为Child-Pugh A级）。对24例（13%）80岁及以上患者和161例（87%）80岁以下患者的数据进行了比较。我们使用倾向评分匹配来调整两组之间的差异。
所有患者的中位总生存期为10.6个月：80岁及以上患者为11.7个月，80岁以下患者为10.5个月。在整个研究队列和倾向评分匹配队列中，80岁及以上患者与80岁以下患者在总生存期、肿瘤反应以及药物相关不良事件的频率和严重程度方面均无显著差异。
索拉非尼可能有效且耐受性良好，即使在80岁及以上的晚期HCC患者以及80岁以下的患者中也是如此。
